Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test
Shares of Bristol Myers Squibb tumbled late Tuesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 study. The post Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test appeared first on Investor's Business Daily.
Shares of Bristol Myers Squibb tumbled late Tuesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 study.
The post Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
